Timing of delivery for placenta accreta spectrum: the Pan-American Society for the Placenta Accreta Spectrum experience


      The Society for Maternal-Fetal Medicine recommends cesarean delivery with potential hysterectomy scheduled in the late preterm period between 34 0/7 and 35 6/7 weeks of gestation for prenatally suspected placenta accreta spectrum.


      We aimed to investigate clinical compliance with the recommended delivery timing window for placenta accreta spectrum and its impact on maternal and neonatal outcomes.


      We performed a retrospective multicenter review of data from referral centers within the Pan-American Society for Placenta Accreta Spectrum. Patients with placenta accreta spectrum with both antenatal diagnosis and confirmed histopathologic findings were included. We investigated adherence to the Society for Maternal-Fetal Medicine-recommended gestational age window for delivery, and compliance was further stratified by scheduled and unscheduled delivery. We compared the outcomes for patients with scheduled delivery within vs immediately 2 weeks outside the recommended window.


      Among 744 patients with a prenatal diagnosis of placenta accreta spectrum and placental histopathologic confirmation, 488 (66%) had scheduled delivery. Among all prenatally diagnosed placenta accreta spectrum patients, 252 (39%) delivered within the recommended window of 34 0/7 and 35 6/7 weeks gestation. For the subgroup of patients who underwent scheduled delivery (n=426), 209 (49%) had delivery in this window, 120 (28%) delivered before 34 weeks, and 97 (23%) delivered at or later than 36 weeks. In the patients with scheduled delivery, 27% of placenta accreta spectrum patients with accreta delivered in the 2 weeks immediately after the recommended window (36 0/7–37 6/7 weeks), and 22% of placenta accreta spectrum pregnancies with increta/percreta delivered in the 2 weeks immediately before the recommended delivery (32 0/7–33 6/7 weeks). The maternal outcomes among those who delivered within the recommended range vs those delivering 2 weeks before and after the recommended range were similar, regardless of placenta accreta spectrum severity.


      Less than half of placenta accreta spectrum patients had scheduled delivery within the recommended gestational age of 34 0/7 to 35 6/7 weeks. The reasons for deviation from recommendations and the risks and benefits of individualized timing of delivery on the basis of risk factors and predicted outcomes warrant further investigation.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology MFM
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mogos MF
        • Salemi JL
        • Ashley M
        • Whiteman VE
        • Salihu HM.
        Recent trends in placenta accreta in the United States and its impact on maternal-fetal morbidity and healthcare-associated costs, 1998–2011.
        J Matern Fetal Neonatal Med. 2016; 29: 1077-1082
        • Society of Gynecologic Oncology
        American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine, Cahill AG, et al. Placenta accreta spectrum.
        Am J Obstet Gynecol. 2018; 219: B2-16
        • Jauniaux E
        • Kingdom JC
        • Silver RM.
        A comparison of recent guidelines in the diagnosis and management of placenta accreta spectrum disorders.
        Best Pract Res Clin Obstet Gynaecol. 2021; 72: 102-116
        • Morlando M
        • Schwickert A
        • Stefanovic V
        • et al.
        Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: a multinational database study.
        Acta Obstet Gynecol Scand. 2021; 100: 41-49
        • Erfani H
        • Fox KA
        • Clark SL
        • et al.
        Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team.
        Am J Obstet Gynecol. 2019; 221: 337.e1-337.e5
        • Shamshirsaz AA
        • Fox KA
        • Erfani H
        • et al.
        Outcomes of planned compared with urgent deliveries using a multidisciplinary team approach for morbidly adherent placenta.
        Obstet Gynecol. 2018; 131: 234-241
        • Silver RM
        • Fox KA
        • Barton JR
        • et al.
        Center of excellence for placenta accreta.
        Am J Obstet Gynecol. 2015; 212: 561-568
        • Shamshirsaz AA
        • Fox KA
        • Erfani H
        • Belfort MA.
        The role of centers of excellence with multidisciplinary teams in the management of abnormal invasive placenta.
        Clin Obstet Gynecol. 2018; 61: 841-850
        • Donovan BM
        • Shainker SA.
        Placenta accreta spectrum.
        NeoReviews. 2021; 22: e722-e733
        • Shamshirsaz AA
        • Fox KA
        • Salmanian B
        • et al.
        Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach.
        Am J Obstet Gynecol. 2015; 212: 218.e1-218.e9
        • Einerson BD
        • Weiniger CF.
        Placenta accreta spectrum disorder: updates on anesthetic and surgical management strategies.
        Int J Obstet Anesth. 2021; 46102975
        • Bowman ZS
        • Manuck TA
        • Eller AG
        • Simons M
        • Silver RM.
        Risk factors for unscheduled delivery in patients with placenta accreta.
        Am J Obstet Gynecol. 2014; 210: 241.e1-241.e6
        • Robinson BK
        • Grobman WA.
        Effectiveness of timing strategies for delivery of individuals with placenta previa and accreta.
        Obstet Gynecol. 2010; 116: 835-842
        • Brenner WE
        • Edelman DA
        • Hendricks CH.
        Characteristics of individuals with placenta previa and results of “expectant management.
        Am J Obstet Gynecol. 1978; 132: 180-191
        • Silver R
        • Depp R
        • Sabbagha RE
        • Dooley SL
        • Socol ML
        • Tamura RK.
        Placenta previa: aggressive expectant management.
        Am J Obstet Gynecol. 1984; 150: 15-22
        • Salmanian B
        • Shainker SA
        • Hecht JL
        • et al.
        The Society for Pediatric Pathology Task Force grading system for placenta accreta spectrum and its correlation with clinical outcomes.
        Am J Obstet Gynecol. 2022; 226 (720.e1–6)
        • Allen L
        • Jauniaux E
        • Hobson S
        • Papillon-Smith J
        • Belfort MA
        FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: nonconservative surgical management.
        Int J Gynaecol Obstet. 2018; 140: 281-290
        • Perlman NC
        • Little SE
        • Thomas A
        • Cantonwine DE
        • Carusi DA.
        Patient selection for later delivery timing with suspected previa-accreta.
        Acta Obstet Gynecol Scand. 2017; 96: 1021-1028
        • Oyelese Y
        • Smulian JC.
        Placenta previa, placenta accreta, and vasa previa.
        Obstet Gynecol. 2006; 107: 927-941
        • Belfort MA
        • Shamshirsaz AA
        • Fox KA.
        The diagnosis and management of morbidly adherent placenta.
        Semin Perinatol. 2018; 42: 49-58
        • Matsubara S
        • Takahashi H
        • Matsubara D
        • Ohkuchi A.
        Timing of surgery for placenta previa with suspected abnormally invasive placentation: a test of team competency?.
        Acta Obstet Gynecol Scand. 2017; 96: 1029
        • Jauniaux E
        • Alfirevic Z
        • Bhide AG
        • et al.
        Royal College of Obstetricians and Gynaecologists. Placenta praevia and placenta accreta: diagnosis and management: Green-top Guideline No. 27a.
        BJOG. 2019; 126: e1-48
        • Collins SL
        • Alemdar B
        • van Beekhuizen HJ
        • et al.
        Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta.
        Am J Obstet Gynecol. 2019; 220: 511-526
        • Hobson SR
        • Kingdom JC
        • Murji A
        • et al.
        383-screening, diagnosis, and management of placenta accreta spectrum disorders.
        J Obstet Gynaecol Can. 2019; 41: 1035-1049
      1. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. guidelines for placenta accreta. Available at:

        • Carniello MO
        • Oliveira Brito LG
        • Starian LOZ
        • Bennini JR
        Diagnosis of placenta accreta spectrum in high-risk women using ultrasonography or magnetic resonance imaging: systematic review to compare accuracy of tests.
        Ultrasound Obstet Gynecol. 2022; 59: 428-436
        • Juan-Clar M
        • Torrent M
        • Santandreu P
        • Arejola E
        • Ibarra J
        • Tubau A.
        Effectiveness of ultrasound screening for a placenta accreta spectrum using standard ultrasound criteria in a secondary care setting.
        Fetal Diagn Ther. 2022; 49: 52-59